The Modern Lipid Playbook Part 2: THE TESTING — Why Your Lipid Panel Isn't Enough

About This Episode

The Modern Lipid Playbook Part 2: THE TESTING — Why Your Lipid Panel Isn't Enough 🚨 2026 ACC/AHA Dyslipidemia Guidelines just dropped — the first update in 8 years. Eleven specialty societies declared ApoB and Lp(a) standard of care. The standard lipid panel is officially not enough. My patient "David" did everything right for 25 years. His LDL was in the 40s — below even the NEW aggressive target. His stress test was normal. But his Lp(a), a genetic risk marker no one had ever checked, was nearly 3x the danger threshold. His CAC score: 1,522. His widowmaker artery: 75-99% blocked. Weeks later, he needed an emergent stent. His wife? Same household. CAC: zero. His brother? CAC: 2,700. In this episode, I break down every blood test and imaging test for heart disease — what each one measures, what it misses, and why CCTA (coronary CT angiography) with AI should be first-line imaging for anyone at risk. *📋 WHAT YOU'LL LEARN:* • Why LDL-C is a calculated estimate from a 1972 equation — and why it misses 1 in 5 patients • ApoB — the $15 test now in the formal clinical risk algorithm • Lp(a) — the genetic marker every adult should know (universal screening recommended) • Why "passing a stress test" may be the most dangerous false reassurance in cardiology • CAC scores — useful but completely blind to the plaque most likely to kill you • CCTA + AI — how it cut heart attacks 41% in SCOT-HEART (sustained at 10 years) • CPT 75577 — AI plaque analysis is now covered by Medicare (effective Jan 2026) • A tiered testing playbook with real costs and insurance tips • How to talk to your doctor when they won't order the right tests *Chapters:* 00:00 25 Years on a Statin — and Still Missed 00:27 The 2026 Guidelines Changed the Standard 01:56 The Standard Lipid Panel’s 1972 Flaw 06:38 ApoB and Lp(a): The Two Tests That Change the Story 13:24 The Truth About Advanced Panels, HDL, & Triglycerides 16:30 The Metabolic Fire: Fasting Insulin & hs-CRP 20:18 Why “Passing a Stress Test” Creates Dangerous False Reassurance 27:19 The CAC Score: Useful, but Blind to Soft Plaque 33:30 CCTA & AI: The New Gold Standard for Plaque Detection 42:15 Insurance Coverage, Microvascular Disease, and Who Gets Missed 46:29 The Tiered Testing Hierarchy & Your Personal Playbook 🔗 LINKS: Part 1 — Why Atherosclerosis Matters: https://youtu.be/fX33g1zFZSo ClearCardio Interview with Dr. John Osborne: https://youtu.be/ihJmKmRC65w Newsletter — The Longevity Letter: https://www.hillarylinmd.com/subscribe 📱 Follow me: - *Instagram:* https://instagram.com/hillarylinmd - *Twitter/X:* https://twitter.com/hillarylinmd - *CareCore (For Clinicians):* https://carecore.io *KEY STUDIES REFERENCED:* • 2026 ACC/AHA Dyslipidemia Guidelines (11 specialty societies; replaces 2018 guidelines) • Sachdeva et al., AHJ 2009 (LDL less than 130 in 72.1%, less than 100 in 49.9% at MI; N=136,905) • Friedewald et al., Clin Chem 1972 • Martin et al., JAMA 2013 (Martin-Hopkins; N=1.35M) [verify JAMA vs. JAMA Intern Med] • Walldius et al., Lancet 2001 (AMORIS; ApoB/ApoA-I ratio; N=175,553) • UK Biobank multimodal risk prediction, JACC (PRS + ApoB + hsCRP; N≈500,000) • Mora et al., Circulation 2009 (LDL-C/ApoB discordance) • Wilkins et al., JACC 2016 (CARDIA 25-year follow-up) • Ference et al., JACC 2018 (Mendelian randomization, lifetime LDL) • Falk et al., Circulation 1995 (~60-68% of MIs from less than 50% stenosis) • Glagov et al., NEJM 1987 (compensatory remodeling) • SCOT-HEART, NEJM 2018 (41% MI/death reduction; N=4,146) • SCOT-HEART 10-year, Lancet 2025 (sustained benefit) • PROMISE, NEJM 2015 (CCTA vs. functional testing; N=10,003) • MESA (Detrano et al., NEJM 2008; multi-ethnic CAC; N=6,814) • Ridker et al., NEJM 2008 (JUPITER; N=17,802) • Ridker et al., NEJM 2017 (CANTOS; N=10,061) • CTT Meta-analysis (170,000+ participants; 22% reduction per mmol/L LDL lowering) • WISE Study (women, non-obstructive CAD mortality) • PESA Study, Circulation 2015 (N=4,184) • MASALA Study (South Asian cardiovascular risk) • Mandsager et al., JAMA Netw Open 2018 (VO2 max; N=122,007) • PROMINENT Trial, NEJM 2022 (N=10,497) • CRISP-CT, Lancet 2018 (pericoronary fat; N=3,912) • BROADWAY Trial (obicetrapib; conference data — verify full pub status) • KETO-CTA Trial, JACC Advances 2025 (Norwitz/Feldman; LMHR + CCTA) • Varbo et al., JACC 2013 (Copenhagen remnant cholesterol MR) #cholesterol #heartdisease #ApoB #CCTA #longevity #preventivemedicine #atherosclerosis #lipids #CCTAscan #2026guidelines